The Study
Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.
This article is like a summary of a bunch of science books and papers about how pancreatic cancer grows. It doesn't do any new experiments, so it can't say for sure that any treatment works — it just tells you what other scientists have noticed or think might be true.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
Pancreatic cancer has a tangled web of broken signals inside its cells and a thick wall of tissue around it that blocks medicine. Even when doctors try to fix one broken signal, others take over.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The results show why current drugs don't work well—cancer cells are smart and use many backup systems, making single treatments ineffective for most patients.
- 2KRAS mutations happen in about 90% of cases; drugs targeting KRAS-G12C or EGFR often fail because other pathways like PI3K or TP53-MDM2 kick in to keep the cancer growing.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Pathology, research and practice
Year
2026
Authors
Nitin Singh, Firoz Ahmad, Adil Husain
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.